Etropal ADXBUL:ETR 50 Gross Margin % is 29.53% as of Dec. 2025, which is 33% below its 10-year median of 44.38. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.59 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Etropal AD ranks worse than 81.94% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Etropal AD's Gross Profit for the
six
months ended in Dec. 2025 was €3.07 Mil. Etropal AD's Revenue for the
six
months ended in Dec. 2025 was €10.39 Mil. Therefore, Etropal AD's Gross Margin % for the quarter that ended in Dec. 2025 was 29.53%.
Warning Sign:
Etropal AD gross margin has been in long-term decline. The average rate of decline per year is -7.2%.
The historical rank and industry rank for Etropal AD's Gross Margin % or its related term are showing as below:
XBUL:ETR'
s Gross Margin % Range Over the Past 10 Years
Min: 24.41 Med: 44.38 Max: 53.59
Current: 29.53
During the past 13 years, the highestGross Margin % of Etropal AD was 53.59%. The lowest was 24.41%. And the median was 44.38%.
XBUL:ETR's Gross Margin % is ranked worse than 81.94% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 52.03
vs XBUL:ETR: 29.53
Etropal AD had a gross margin of 29.53% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Etropal AD was -7.20% per year.
Etropal AD (XBUL:ETR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Etropal AD had a gross margin of 29.53% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Etropal AD Gross Margin % Related Terms
Etropal AD Gross Margin % Historical Data
* Premium members only.
The historical data trend for Etropal AD's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Etropal AD's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Etropal AD (XBUL:ETR) has a Gross Margin % of 29.53% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Etropal AD and its competitors. This is 33% below median its historical median of 44.38. Over the past decade, Etropal AD's Gross Margin % has ranged from 24.41 to 53.59. According to the industry distribution chart, Etropal AD ranks #658 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 81.9%.
Is Etropal AD's Gross Margin % too high?
Etropal AD's current Gross Margin % of 29.53% is 33% below median its 10-year median of 44.38. Over the past 10 years, this metric has ranged from a low of 24.41 to a high of 53.59. The Medical Devices & Instruments industry median Gross Margin % is 52.03. Etropal AD's value of 29.53% is 43.2% below this industry median. Based on the distribution chart, Etropal AD ranks #658 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #658 out of 803 companies for Gross Margin %. This places Etropal AD in the lower half of its industry. The industry median Gross Margin % is 52.03. Etropal AD's value of 29.53% is 43.2% below this benchmark. Historically, Etropal AD's own Gross Margin % has ranged from 24.41 to 53.59 over the past decade. While the company's 10-year median is 44.38 vs. the industry median of 52.03, Etropal AD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.03, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current Gross Margin % of 29.53% is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current Gross Margin % is 29.53%, which is 33% below median its own 10-year median of 44.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.59, compared to a current price of €2.52 — trading 70.7% below its estimated fair value. The current Gross Margin % is 29.53%, which is 33% below median its 10-year median of 44.38 and 43.2% below the Medical Devices & Instruments industry median of 52.03. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current Gross Margin % is 29.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.52 is trading 70.7% below its estimated GF Value™ of €8.59.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
Gross Margin %: 29.53% (33% below median its 10-year median of 44.38)
GF Value™: €8.59 vs. price of €2.52 (70.7% below fair value)
Industry Position: 43.2% below the Medical Devices & Instruments median (#658 of 803)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
